This 157-page report, “Global Virus Filtration Market 2020-2026 by Product (Consumables, Instruments, Services), Application, End User, and Region: COVID-19 Impact and Growth Opportunity,” is highlighted by 84 tables and 78 figures and is based on an in-depth analysis of the entire global virus filtration market and all of its sub-segments. Premium primary and secondary information sources are used to create in-depth research and evaluation, with input coming from business specialists working throughout the value chain.
The rapid development of the pharmaceutical and biotechnology industries, rising R&D expenditures, and the rising demand for virus removal and clearance due to the COVID-19 pandemic will all contribute to the global virus filtration market reaching $6,275.3 million by 2026, growing by 12.26% annually over 2020–2026.
The study uses 2019 as the foundation year for forecasts from 2020 to 2026 and is based on research from 2016 to 2019. (Please note that the report will be updated before to delivery to ensure that the forecast includes at least 5 years beyond the base year and the most recent historical year serves as the base year.)
Request Research Sample with Latest Industry Insights: https://altusmarketresearch.com/reports/sample/3463
The following elements are identified and examined in-depth qualitative analyses:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
By taking COVID-19 into consideration, the trend and prognosis for the global market are predicted with an upbeat, fair-minded, and cautious viewpoint. The worldwide viral filtration market is quantified from the viewpoints of Product, Application, End User, and Region using the balanced (most likely) forecast.
Based on Product, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
Consumables
Instruments
• Filtration Systems
• Chromatography systems
Services
Based on Application, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
Biological Applications
• Vaccines and Therapeutics
• Blood and Blood Products
• Cellular and Gene Therapy Products
• Tissue and Tissue Products
• Stem Cell Products
Medical Devices
Water Purification
Air Purification
Other Applications
Based on End User, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
• Pharmaceutical and Biotechnology Companies
• Contract Research Organisations (CROs)
• Academic & Research Institutes
• Medical Device Companies
• Other End Users
Along with the above national/local markets, the following geographic areas are thoroughly investigated:
• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)
In Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)
• America, North (U.S., Canada, and Mexico)
Latin America (Brazil, Columbia, Argentina, Rest of South America)
• MEA (Saudi Arabia, UAE, South Africa)
Detailed analysis and statistics for yearly revenue ($ mn) for each area and important nation are accessible for the years 2016 through 2026. There is also a breakdown of the major national markets by Product, Application, and End User during the projection years, as well as a breakdown of the regional markets by country.
The study also analyses the present competition landscape, the anticipated trend, and it provides profiles of major suppliers, including both established market leaders and significant up-and-coming companies.
Through AMR’s Risk Assessment System, possible risks related to investing in the worldwide viral filtering market are specifically assessed quantitatively and qualitatively. Critical Success Factors (CSFs) are developed based on the risk analysis and assessment as a guide to assist investors and shareholders in identifying new possibilities, managing and minimising risks, developing suitable business models, and making informed strategies and choices.
Key Players (this list may not be exhaustive; other businesses may be included upon request):
Asahi Kasei Medical Co., Ltd.
Charles River Laboratories International, Inc.
Clean Cells
General Electric Company
Lonza Group AG
Merck KGaA
MilliporeSigma
Pall Corporation
Sartorius AG
Thermo Fisher Scientific, Inc.
Wuxi Apptec
